Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 4Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Squamous Cell 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Allogeneic Stem Cell Transplantation × decitabine and cedazuridine drug combination × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡